🇺🇸 FDA
Patent

US 10538530

Vasopressin receptor antagonists and products and methods related thereto

granted A61PA61P25/00A61P25/18

Quick answer

US patent 10538530 (Vasopressin receptor antagonists and products and methods related thereto) held by BLACKTHORN THERAPEUTICS, INC. expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BLACKTHORN THERAPEUTICS, INC.
Grant date
Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
104
CPC classes
A61P, A61P25/00, A61P25/18, A61P25/20, A61P25/22